Back to Journals » Vascular Health and Risk Management » Volume 8

Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

Authors Shuster J, Bleske, Dorsch MP

Received 21 January 2012

Accepted for publication 1 March 2012

Published 13 June 2012 Volume 2012:8 Pages 381—387


Review by Single anonymous peer review

Peer reviewer comments 3

Jerrica E Shuster,1,2 Barry E Bleske,1,2 Michael P Dorsch1,2

1University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2College of Pharmacy, University of Michigan, Ann Arbor, MI, USA

Abstract: Azilsartan–chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension.

Keywords: azilsartan, chlorthalidone, combination, hypertension

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.